IMCR (Immunocore Holdings) Short Interest


IMCR Immunocore Holdings PLC IMCR
72 GF Score
Price $29.99
GF Value $46.10
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Immunocore Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IMCR vs MAZE, FTRE, ARDX: Short Interest Comparison

For the Biotechnology subindustry, Immunocore Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's Short Interest falls into.


IMCR
72GF Score
Immunocore Holdings PLC IMCR
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Immunocore Holdings (IMCR) Overvalued in 2026?

Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued. The current stock price of $29.99 is trading 34.9% below its estimated GF Value™ of $46.10. GuruFocus considers Immunocore Holdings to be Possible Value Trap.

Key valuation signals for IMCR:

  • Short Interest:
  • GF Value™: $46.10 vs. price of $29.99 (34.9% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunocore Holdings Business Description

Other Exchanges 6YG:Germany
Address 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
72GF Score

Get the complete analysis for IMCR

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.99
Price
$46.10
GF Value